Please login to the form below

Not currently logged in
Email:
Password:

bmore creative hires Kush Rach as new business director

Independent agency appoints former Pulsar Healthcare business development director

Kush Rach bmore creativeUK-based multichannel agency bmore creative has appointed Kush Rach as its new business director.

Rach previously spent nearly three years with Pulsar Healthcare as its business development director and prior to that served industry-side at Novartis.

He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2 diabetes.

Ben Blackmore, bmore creative's MD, told The Directory: "We are delighted to welcome Kush into our growing team here at bmore creative. Kush went through a very competitive and difficult recruitment process to become our new business director here.

“His excellent industry knowledge and dynamic personality are just two of the reasons he was selected over and above the other candidates."

Before his time at Novartis, Rach was business development manager at the pre- and post-launch medical communications agency Zaicom MMC, where he worked on global communications projects for GSK Bio, Ferring and Lundbeck.

Having gained his degree in pharmacology at University of Aberdeen, Rach initially joined Altana Pharma as a medical representative before becoming a key account manager at Teva and business development manager at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).

20th March 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics